Orthotopic MCF7 breast adenocarcinoma (NOD-SCID gamma)
preclinical tumor model from the MiTO database
  • orthotopic transplantation into estrogen supplemented NOD-SCID gamma female mice

    in growth factor-reduced Matrigel

  • adenocarinoma of breast fat pad injection mammary gland estrogen pellet orthotopic MCF7-xenograft MCF7-heterotransplantation tumor

Manipulations and tumor entities

    • subcutaneous injection of 90 day-release pellets from Innovative Research of America by means of a trochar (Innovative Research of America) into the neck fold 5 to 7 days prior to cell implantation

    • (1,7 mg estrogen/pellet)

    • every 90 days

    • breast cancer cell

    • under short-term isoflurane anesthesia: 5 million cells/30 µl PBS:Matrigel (growth factor reduced, Becton Dickinson), (1:1; VOL/VOL) into the fat pad of the 4th mammary gland

    • orthotopically

    • 20 days latency period, outgrowth of mammary gland tumors, 1.0 cm in diameter in one dimension 12 weeks after transplantation, take-rate: 100 %

    • mammary gland adenocarcinoma

Available at

  • Tumor Models (W420)
  • DKFZ (German Cancer Research Center)
  • Priv. Doz. Dr. Karin Müller-Decker
  • 12/8/2017 11:35:56 AM
  • 12/13/2017 5:14:33 PM
  • Original

Are you sure you want to delete this tumor model?

Report model for being

Please describe why the model requires administrator intervention

A report message is send to the administrator.